Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Shuffles Senior Bureaucrats, Miyamoto to Head Pharma Safety Bureau
Japan’s Ministry of Health, Labor and Welfare (MHLW) on July 1 unveiled a reshuffled roster of senior officials with their appointments effective July 8. Councilor Naoki Miyamoto has been tapped as new director-general of the Pharmaceutical Safety Bureau. Miyamoto, currently…
To read the full story
Related Article
- MHLW Veteran Katsufumi Jo Joins BCG as Senior Advisor
November 5, 2025
- MHLW’s New Pharma Chief Pledges Safer, More Accessible Drug Environment
August 19, 2025
- Public-Private Council WG to Focus on Innovation Evaluation for FY2026 Reform: Official
August 8, 2025
- MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies
August 6, 2025
- MHLW Official Urges Use of New Fund to Drive Reorganization of Generic Sector
August 4, 2025
- Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
- Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
- New MHLW Drug Review Chief Aims to Dispel “Barrier” Perception, Pledges Active Engagement with Industry
July 23, 2025
REGULATORY
- Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
March 24, 2026
- Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026
- Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
March 24, 2026
- MHLW Panel Calls for Careful Design of OTC-Like Drug Charge System
March 23, 2026
- Japan Hands Out Orphan Tags to Ianalumab, Bleximenib, and Lots More Drugs
March 23, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…